OM
VYGR icon

Opaleye Management’s Voyager Therapeutics VYGR Stock Holding History

Opaleye Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15M Buy
1,185,000
+35,000
+3% +$133K 0.38% 39
2026
Q1 		$4.44M Sell
1,150,000
-46,904
-4% -$185K 0.58% 34
2025
Q4 		$4.7M Buy
+1,196,904
New +$5.29M 0.62% 31

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Opaleye Management's VYGR Position: Q2 2026 in Review

Opaleye Management increased its Voyager Therapeutics (VYGR) stake by 3% in Q2 2026, buying an estimated $133K and bringing the position to 1,185,000 shares worth $4.15M. The position accounts for 0.38% of the portfolio, ranked #39.

Opaleye Management first reported a position in VYGR in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.7M in Q4 2025. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Opaleye Management held 1,185,000 shares of Voyager Therapeutics worth $4.15M as of Q2 2026.
  • Opaleye Management bought 35,000 Voyager Therapeutics shares in Q2 2026, an estimated $133K.
  • Voyager Therapeutics made up 0.38% of Opaleye Management's portfolio in Q2 2026, its #39 holding.
  • Opaleye Management first reported a position in Voyager Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Opaleye Management's Voyager Therapeutics position peaked at $4.7M in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.